Shares of Emergent Biosolutions Inc (NYSE:EBS) have earned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $61.86.

Several analysts have recently weighed in on the stock. Cantor Fitzgerald set a $68.00 price objective on shares of Emergent Biosolutions and gave the company a “buy” rating in a research report on Tuesday, September 11th. Argus raised their price objective on shares of Emergent Biosolutions to $70.00 and gave the company an “average” rating in a research report on Tuesday, September 11th. They noted that the move was a valuation call. Chardan Capital raised their price objective on shares of Emergent Biosolutions from $60.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, September 4th. Cowen restated a “hold” rating and set a $49.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, August 29th. Finally, Wells Fargo & Co set a $65.00 price objective on shares of Emergent Biosolutions and gave the company a “hold” rating in a research report on Wednesday, August 29th.

Emergent Biosolutions stock opened at $64.89 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.15 and a current ratio of 5.59. The firm has a market cap of $3.25 billion, a PE ratio of 34.15, a P/E/G ratio of 1.37 and a beta of 1.25. Emergent Biosolutions has a fifty-two week low of $36.38 and a fifty-two week high of $65.30.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.19. The firm had revenue of $220.20 million for the quarter, compared to analysts’ expectations of $208.94 million. Emergent Biosolutions had a net margin of 16.55% and a return on equity of 15.09%. The business’s quarterly revenue was up 118.5% on a year-over-year basis. During the same quarter last year, the company posted $0.13 EPS. equities analysts forecast that Emergent Biosolutions will post 2.37 earnings per share for the current year.

In related news, Chairman Fuad El-Hibri sold 15,000 shares of the stock in a transaction on Monday, July 9th. The shares were sold at an average price of $53.61, for a total transaction of $804,150.00. Following the transaction, the chairman now owns 1,539,993 shares of the company’s stock, valued at approximately $82,559,024.73. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Daniel Abdun-Nabi sold 90,776 shares of the stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $60.18, for a total transaction of $5,462,899.68. Following the transaction, the chief executive officer now directly owns 257,343 shares in the company, valued at approximately $15,486,901.74. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 165,087 shares of company stock worth $9,597,369. 13.40% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in EBS. Stratos Wealth Partners LTD. bought a new stake in Emergent Biosolutions in the 1st quarter worth $134,000. PNC Financial Services Group Inc. grew its holdings in Emergent Biosolutions by 108.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 1,482 shares during the last quarter. SG Americas Securities LLC bought a new stake in Emergent Biosolutions in the 1st quarter worth $171,000. Financial Gravity Wealth Inc. bought a new stake in Emergent Biosolutions in the 1st quarter worth $190,000. Finally, Sei Investments Co. grew its holdings in Emergent Biosolutions by 5,992.1% in the 1st quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 3,775 shares during the last quarter. 83.00% of the stock is currently owned by institutional investors and hedge funds.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: What is a Tariff?

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.